HDAC6 and Hepatic fibrosis: Here we make a case for further investigation of the anti‐fibrotic potential of targeting HDAC6 in the diseased liver by synthesizing two novel small molecule inhibitors and demonstrating their ability to inhibit TGF‐β1 signaling in HSC and suppress induced liver fibrosis in the hPCLS model of human liver fibrosis.